37 citations
,
December 2019 in “Giornale italiano di dermatologia e venereologia” The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
Hair loss in young men in Central India is linked to severe heart disease.
32 citations
,
April 2006 in “The Journal of Urology” Using finasteride with TIP extends time off period for prostate cancer patients.
November 1968 in “Journal of the American Pharmaceutical Association” 4 citations
,
May 1958 in “Journal of Investigative Dermatology”
January 2023 in “Indian dermatology online journal” A child with trichothiodystrophy also had autoimmune thyroiditis and anemia, which is a new finding.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
1 citations
,
May 2008 in “Toxicon” The lowest effective dose of Botox for detrusor sphincter dyssynergia is between 75-100 units.
February 2021 in “Reactions Weekly” Finasteride and dutasteride may cause macular abnormalities.
January 2005 in “Translational and Clinical Pharmacology” HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
September 2024 in “International Journal of Applied Pharmaceutics” A reliable method was developed to measure Finasteride and Tadalafil in rat blood.
14 citations
,
November 2011 in “Journal of The American Academy of Dermatology” Alopecia Areata Incognita causes widespread hair thinning, and treatment with systemic corticosteroids and psychiatric support can lead to remission.
22 citations
,
January 2018 in “European urology focus” New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
23 citations
,
January 2021 in “Biomedicine & Pharmacotherapy” DHT stops hair regrowth in mice, similar to human hair loss.
April 2023 in “Journal of Investigative Dermatology” cp-asiAR may effectively treat hair loss by targeting androgen receptors.
August 2016 in “Journal of Investigative Dermatology” Dutasteride improved hair density and thickness in men not helped by finasteride, with minimal side effects.
April 2025 in “Pharmaceuticals” APA is a promising new compound for repairing damaged hair, outperforming Olaplex® in strength and elasticity.
December 2024 in “Journal of Cancer Therapy and Research” Artocarpus heterophyllus seed extract may help treat prostate inflammation without side effects.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism”
September 2024 in “Cureus” A new method improves platelet testing for heart disease patients.
18 citations
,
February 2014 in “PubMed” Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.
2 citations
,
December 2021 in “Korean Journal of Clinical Pharmacy”
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
June 2023 in “Value in Health” Alopecia areata treatments often cause headaches and infections, highlighting the need for safer options.
24 citations
,
October 2018 in “Addiction Biology” Alcohol dependence affects stress hormone levels more than childhood maltreatment.
1 citations
,
January 2010 in “Endocrine abstracts”